Ronald Kasoma Mutebi, Andrew Weil Semulimi, John Mukisa, Martha Namusobya, Joy Christine Namirembe, Esther Alice Nalugga, Charles Batte, David Mukunya, Bruce Kirenga, Robert Kalyesubula, Pauline Byakika-Kibwika
{"title":"乌干达接受多路地韦为基础的抗逆转录病毒治疗的成人高血压患病率及相关因素:一项横断面研究","authors":"Ronald Kasoma Mutebi, Andrew Weil Semulimi, John Mukisa, Martha Namusobya, Joy Christine Namirembe, Esther Alice Nalugga, Charles Batte, David Mukunya, Bruce Kirenga, Robert Kalyesubula, Pauline Byakika-Kibwika","doi":"10.2147/IBPC.S403023","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dolutegravir-based anti-retroviral therapy (ART) regimens were rolled out as first line HIV treatment in Uganda due to their tolerability, efficacy and high resistance barrier to human immunodeficiency virus (HIV). They have however been associated with weight gain, dyslipidemia and hyperglycemia which are cardiometabolic risk factors of hypertension. We assessed the prevalence and factors associated with hypertension among adults on dolutegravir regimens.</p><p><strong>Methods: </strong>We conducted a cross-sectional study on 430 systematically sampled adults on dolutegravir-based ART for ≥ 6 months. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or history of use of antihypertensive agents.</p><p><strong>Results: </strong>The prevalence of hypertension was 27.2% (117 of 430 participants) [95% CI: 23.2-31.6]. Majority were female (70.7%), the median age 42 [34, 50] years, with body mass index (BMI) ≥ 25 kg/m<sup>3</sup> (59.6%) and median duration on DTG-based regimens of 28 [15, 33] months. Being male [aPR: 1.496, 95% CI: 1.122-1.994, P = 0.006], age ≥ 45 years [aPR: 4.23, 95% CI: 2.206-8.108, P < 0.001] and 35-44 years [aPR: 2.455, 95% CI: 1.216-4.947, P < 0.012] as compared with age < 35 years, BMI ≥ 25 kg/m<sup>3</sup> [aPR: 1.489, 95% CI: 1.072-2.067, P = 0.017] as compared with BMI < 25 kg/m<sup>3</sup>, duration on dolutegravir-based ART [aPR: 1.008, 95% CI: 1.001-1.015, P = 0.037], family history of hypertension [aPR: 1.457, 95% CI: 1.064-1.995, P = 0.019] and history of heart disease [aPR: 1.73, 95% CI: 1.205-2.484, P = 0.003] were associated with hypertension.</p><p><strong>Conclusion: </strong>One in every four people with HIV (PWH) on dolutegravir-based ART has hypertension. We recommend the integration of hypertension management in the HIV treatment package and policies to improve existing supply chains for low cost and high-quality hypertension medications.</p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/f2/ibpc-16-11.PMC10123006.pdf","citationCount":"2","resultStr":"{\"title\":\"Prevalence of and Factors Associated with Hypertension Among Adults on Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross Sectional Study.\",\"authors\":\"Ronald Kasoma Mutebi, Andrew Weil Semulimi, John Mukisa, Martha Namusobya, Joy Christine Namirembe, Esther Alice Nalugga, Charles Batte, David Mukunya, Bruce Kirenga, Robert Kalyesubula, Pauline Byakika-Kibwika\",\"doi\":\"10.2147/IBPC.S403023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dolutegravir-based anti-retroviral therapy (ART) regimens were rolled out as first line HIV treatment in Uganda due to their tolerability, efficacy and high resistance barrier to human immunodeficiency virus (HIV). They have however been associated with weight gain, dyslipidemia and hyperglycemia which are cardiometabolic risk factors of hypertension. We assessed the prevalence and factors associated with hypertension among adults on dolutegravir regimens.</p><p><strong>Methods: </strong>We conducted a cross-sectional study on 430 systematically sampled adults on dolutegravir-based ART for ≥ 6 months. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or history of use of antihypertensive agents.</p><p><strong>Results: </strong>The prevalence of hypertension was 27.2% (117 of 430 participants) [95% CI: 23.2-31.6]. Majority were female (70.7%), the median age 42 [34, 50] years, with body mass index (BMI) ≥ 25 kg/m<sup>3</sup> (59.6%) and median duration on DTG-based regimens of 28 [15, 33] months. Being male [aPR: 1.496, 95% CI: 1.122-1.994, P = 0.006], age ≥ 45 years [aPR: 4.23, 95% CI: 2.206-8.108, P < 0.001] and 35-44 years [aPR: 2.455, 95% CI: 1.216-4.947, P < 0.012] as compared with age < 35 years, BMI ≥ 25 kg/m<sup>3</sup> [aPR: 1.489, 95% CI: 1.072-2.067, P = 0.017] as compared with BMI < 25 kg/m<sup>3</sup>, duration on dolutegravir-based ART [aPR: 1.008, 95% CI: 1.001-1.015, P = 0.037], family history of hypertension [aPR: 1.457, 95% CI: 1.064-1.995, P = 0.019] and history of heart disease [aPR: 1.73, 95% CI: 1.205-2.484, P = 0.003] were associated with hypertension.</p><p><strong>Conclusion: </strong>One in every four people with HIV (PWH) on dolutegravir-based ART has hypertension. We recommend the integration of hypertension management in the HIV treatment package and policies to improve existing supply chains for low cost and high-quality hypertension medications.</p>\",\"PeriodicalId\":45299,\"journal\":{\"name\":\"Integrated Blood Pressure Control\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/f2/ibpc-16-11.PMC10123006.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrated Blood Pressure Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/IBPC.S403023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated Blood Pressure Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IBPC.S403023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 2
摘要
导语:基于dolutegravvir的抗逆转录病毒疗法(ART)方案由于其耐受性、有效性和对人类免疫缺陷病毒(HIV)的高抗性屏障,在乌干达作为一线艾滋病毒治疗方案推出。然而,它们与体重增加、血脂异常和高血糖有关,这些都是高血压的心脏代谢危险因素。我们评估了使用多替格拉韦治疗的成年人中高血压的患病率和相关因素。方法:我们对430名系统抽样的成年人进行了横断面研究,这些成年人接受了以盐酸孕酮为基础的抗逆转录病毒治疗≥6个月。高血压被定义为收缩压≥140 mmHg或舒张压≥90 mmHg或使用抗高血压药物的历史。结果:高血压患病率为27.2% (117 / 430)[95% CI: 23.2-31.6]。大多数为女性(70.7%),中位年龄42[34,50]岁,体重指数(BMI)≥25 kg/m3(59.6%),以dtg为基础的方案中位持续时间为28[15,33]个月。被男性[4月:1.496,95%置信区间CI: 1.122 - -1.994, P = 0.006),≥45岁(4月:4.23,95%置信区间CI: 2.206 - -8.108, P < 0.001]和35-44年[4月:2.455,95%置信区间CI: 1.216 - -4.947, P < 0.012),与年龄< 35年,BMI≥25公斤/立方米(4月:1.489,95%置信区间CI: 1.072 - -2.067, P = 0.017)与体重指数< 25公斤/立方米,持续时间dolutegravir-based艺术[4月:1.008,95%置信区间CI: 1.001 - -1.015, P = 0.037),高血压家族史(4月:1.457,95%置信区间CI: 1.064 - -1.995, P = 0.019)和心脏病史的[4月:[1.73, 95% CI: 1.205 ~ 2.484, P = 0.003]与高血压相关。结论:每4名接受以盐酸孕酮为基础的抗逆转录病毒治疗的HIV感染者中就有1人患有高血压。我们建议将高血压管理纳入艾滋病毒治疗方案和政策,以改善低成本和高质量高血压药物的现有供应链。
Prevalence of and Factors Associated with Hypertension Among Adults on Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross Sectional Study.
Introduction: Dolutegravir-based anti-retroviral therapy (ART) regimens were rolled out as first line HIV treatment in Uganda due to their tolerability, efficacy and high resistance barrier to human immunodeficiency virus (HIV). They have however been associated with weight gain, dyslipidemia and hyperglycemia which are cardiometabolic risk factors of hypertension. We assessed the prevalence and factors associated with hypertension among adults on dolutegravir regimens.
Methods: We conducted a cross-sectional study on 430 systematically sampled adults on dolutegravir-based ART for ≥ 6 months. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or history of use of antihypertensive agents.
Results: The prevalence of hypertension was 27.2% (117 of 430 participants) [95% CI: 23.2-31.6]. Majority were female (70.7%), the median age 42 [34, 50] years, with body mass index (BMI) ≥ 25 kg/m3 (59.6%) and median duration on DTG-based regimens of 28 [15, 33] months. Being male [aPR: 1.496, 95% CI: 1.122-1.994, P = 0.006], age ≥ 45 years [aPR: 4.23, 95% CI: 2.206-8.108, P < 0.001] and 35-44 years [aPR: 2.455, 95% CI: 1.216-4.947, P < 0.012] as compared with age < 35 years, BMI ≥ 25 kg/m3 [aPR: 1.489, 95% CI: 1.072-2.067, P = 0.017] as compared with BMI < 25 kg/m3, duration on dolutegravir-based ART [aPR: 1.008, 95% CI: 1.001-1.015, P = 0.037], family history of hypertension [aPR: 1.457, 95% CI: 1.064-1.995, P = 0.019] and history of heart disease [aPR: 1.73, 95% CI: 1.205-2.484, P = 0.003] were associated with hypertension.
Conclusion: One in every four people with HIV (PWH) on dolutegravir-based ART has hypertension. We recommend the integration of hypertension management in the HIV treatment package and policies to improve existing supply chains for low cost and high-quality hypertension medications.